Firvanq

Last updated on RxList: 2/12/2021
Firvanq Side Effects Center

What Is Firvanq?

Firvanq (vancomycin hydrochloride) is a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of: Clostridium difficile-associated diarrhea, and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

What Are Side Effects of Firvanq?

Common side effects of Firvanq include:

Dosage for Firvanq

The adult dose of Firvanq to treat Clostridium difficile-associated diarrhea is 125 mg orally 4 times daily for 10 days. The pediatric dose of Firvanq to treat Clostridium difficile-associated diarrhea is 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The adult dose of Firvanq to treat staphylococcal enterocolitis is 500 mg to 2 g orally in 3 or 4 divided doses for 7 to 10 days. The pediatric dose of Firvanq to treat staphylococcal enterocolitis is 40 mg/kg in 3 or 4 divided doses for 7 to 10 days.

What Drugs, Substances, or Supplements Interact with Firvanq?

Firvanq may interact with other drugs. Tell your doctor all medications and supplements you use.

Firvanq During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Firvanq; it is unknown how it would affect a fetus. It is unknown if Firvanq passes into breast milk. Systemic absorption of vancomycin following oral administration is expected to be minimal. Consult your doctor before breastfeeding.

Additional Information

Our Firvanq (vancomycin hydrochloride), for Oral Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

Pancreatitis is inflammation of an organ in the abdomen called the pancreas. See Answer
Firvanq Consumer Information

3 pharmacies near 20147 have coupons for FIRST-Vancomycin 25 (Brand Names:Firvanq for 125MG)

Costco
Costco
$1103.06

Est. Regular Price

$63.99

with free coupon

View Coupon
Walmart Pharmacy
Walmart Pharmacy
$1455.07

Est. Regular Price

$77.38

with free coupon

View Coupon
Harris Teeter Pharmacy
Harris Teeter Pharmacy
$933.19

Est. Regular Price

$93.01

with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Certain side effects may occur if your body absorbs vancomycin through the intestinal walls. Call your doctor at once if you have:

  • increased diarrhea that is watery or bloody;
  • hearing loss, ringing in your ears;
  • kidney problems--swelling, rapid weight gain, pain in your side or lower back, little or no urination; or
  • low potassium level--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling.

Side effects on the kidneys may be more likely in older adults taking this medicine.

Common side effects may include:

  • low potassium;
  • nausea; or
  • stomach pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Firvanq (Vancomycin Hydrochloride for Oral Solution)

SLIDESHOW

Super Tips to Boost Digestive Health: Bloating, Constipation, and More See Slideshow
Firvanq Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to vancomycin hydrochloride in 260 adult subjects in two Phase 3 clinical trials for the treatment of C. difficile-associated diarrhea. In both trials, subjects received vancomycin hydrochloride 125 mg orally four times daily. The mean duration of treatment was 9.4 days. The median age of patients was 67, ranging between 19 and 96 years of age. Patients were predominantly Caucasian (93%), and 52% were male.

Adverse reactions occurring in ≥ 5% of vancomycin hydrochloride-treated subjects are shown in Table 2. The most common adverse reactions associated with vancomycin hydrochloride (≥ 10%) were nausea, abdominal pain, and hypokalemia.

Table 2: Common (≥ 5%) Adverse Reactions* for Vancomycin Hydrochloride Reported in Clinical Trials for Treatment of C. difficile-Associated Diarrhea

System/Organ ClassAdverse ReactionVancomycin Hydrochloride (%)
(N=260)
Gastrointestinal disordersNausea17
Abdominal pain15
Vomiting9
Diarrhea9
Flatulence8
General disorders and administration site conditionsPyrexia9
Edema peripheral6
Fatigue5
Infections and infestationsUrinary tract infection8
Metabolism and nutrition disordersHypokalemia13
Musculoskeletal and connective tissue disordersBack pain6
Nervous system disordersHeadache7
* Adverse reaction rates were derived from the incidence of treatment-emergent adverse events.

Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) occurred in 5% of subjects treated with vancomycin hydrochloride. Nephrotoxicity following vancomycin hydrochloride typically first occurred within one week after completion of treatment (median day of onset was Day 16). Nephrotoxicity following vancomycin hydrochloride occurred in 6% of subjects over 65 years of age and 3% of subjects 65 years of age and younger [see WARNINGS AND PRECAUTIONS]. Nephrotoxicity can also occur during oral vancomycin administration.

The incidences of hypokalemia, urinary tract infection, peripheral edema, insomnia, constipation, anemia, depression, vomiting, and hypotension were higher among subjects over 65 years of age than in subjects 65 years of age and younger [see Use In Specific Populations].

Discontinuation of study drug due to adverse events occurred in 7% of subjects treated with vancomycin hydrochloride. The most common adverse events leading to discontinuation of vancomycin hydrochloride were C. difficile colitis (< 1%), nausea (< 1%), and vomiting (< 1%).

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of vancomycin hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Ototoxicity

Cases of hearing loss associated with intravenously administered vancomycin have been reported. Most of these patients had kidney dysfunction or a preexisting hearing loss or were receiving concomitant treatment with an ototoxic drug [see WARNINGS AND PRECAUTIONS]. Vertigo, dizziness, and tinnitus have been reported.

Skin And Subcutaneous Tissue Disorders

Severe dermatologic reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear lgA bullous dermatosis (LABD) [see WARNINGS AND PRECAUTIONS], rashes (including exfoliative dermatitis).

Hematopoietic

Reversible neutropenia, usually starting 1 week or more after onset of intravenous therapy with vancomycin or after a total dose of more than 25 g, has been reported. Neutropenia appears to be promptly reversible when vancomycin is discontinued. Thrombocytopenia has been reported.

Miscellaneous

Anaphylaxis, drug fever, chills, nausea, eosinophilia, and vasculitis have been reported with the administration of vancomycin.

A condition has been reported with oral vancomycin that is similar to the IV-induced syndrome with symptoms consistent with anaphylactoid reactions, including hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (“Red Man Syndrome”), pain and muscle spasm of the chest and back. These reactions usually resolve within 20 minutes but may persist for several hours.

Read the entire FDA prescribing information for Firvanq (Vancomycin Hydrochloride for Oral Solution)

© Firvanq Patient Information is supplied by Cerner Multum, Inc. and Firvanq Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors